Indivior Pharmaceuticals (INDV) Asset Writedowns and Impairment (2024 - 2026)

Indivior Pharmaceuticals' Asset Writedowns and Impairment history runs 3 years deep, the most recent figure standing at $6.0 million for Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $6.0 million in Q1 2026; TTM through Mar 2026 was $25.0 million, a 257.14% increase from a year earlier, with the FY2025 full-year figure at $19.0 million, up 137.5% from the prior year.
• Asset Writedowns and Impairment climbed to $6.0 million in Q1 2026 per INDV's latest filing, from $3.0 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $16.0 million in Q3 2025 and bottomed at $1.0 million in Q1 2024.
• The 3-year median for Asset Writedowns and Impairment is $6.0 million (2026), against an average of $6.6 million.